Trial
NCT00120289
Niacin Plus Statin to Prevent Vascular Events
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Axio Research. LLC
Collaborators
National Heart, Lung, and Blood Institute (NHLBI); Abbott
Condition
Cardiovascular Diseases
Intervention
Extended release niacin
Why stopped
AIM-HIGH was stopped on the recommendation of the DSMB because of lack of efficacy of niacin in preventing primary outcome events.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-04-06